NOVATO, Calif., Sept. 17 /PRNewswire-FirstCall/ -- BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) announced today that it has licensed to Asubio Pharma Co., Ltd. (a subsidiary of Daiichi Sankyo) exclusive rights to data and intellectual property contained in the Kuvan(TM) (sapropterin dihydrochloride) new drug application (NDA). Asubio will use this data to supplement its current filing to the Japanese Ministry of Health, Labour and Welfare for approval of its BH4 product for the treatment of phenylketonuria (PKU) in Japan. The application is for a label extension for its current BH4 product marketed in Japan for primary BH4 deficiency. Kuvan is an investigational oral small molecule for the treatment of PKU being developed in partnership with Merck Serono, a division of Merck KGaA, Darmstadt, Germany. BH4 is the active ingredient in Kuvan.
"We have had a long-standing relationship with Asubio regarding BH4 as their early work on BH4 was important to our success in Kuvan development. We are pleased to finalize this new agreement to facilitate approval in Japan. While Asubio already holds the exclusive rights to its own data to commercialize BH4 for all indications in Japan, this new data greatly expands the clinical data set on treatment of PKU and is expected to accelerate the timing for the label extension of Asubio's current BH4 product," said Jean-Jacques Bienaime, Chief Executive Officer of BioMarin.
BioMarin will receive a milestone payment for approval as well as double-digit royalties on net sales of BH4 for PKU in Japan.
Kuvan is an investigational oral small molecule therapeutic for the
treatment of PKU. The active ingredient in Kuvan, sapropterin
dihydrochloride, is the synthetic form of 6R-BH4 (tetrahydrobiopterin), a
naturally occurring enzyme cofactor that works in conjunction with
phenylalanine hydroxylase (PAH) to metabolize Phe. Clinical data suggest
that treatment with Kuvan results in significant red
|SOURCE BioMarin Pharmaceutical Inc.|
Copyright©2007 PR Newswire.
All rights reserved